blindness from glp-1 Lipsitz, Ponterio & Comerford GLP-1s and Eye Health: What

Description

However, Tresiba remains essential for patients who need direct insulin replacement, particularly those with type 1 diabetes or advanced type 2 diabetes with significant beta cell failure

Acceptable alternatives to scintigraphy include the 13 C stable isotope breath test and ultrasonography

Semaglutide vs Tirzepatide: The Core Differences Comparison point Semaglutide Tirzepatide Hormone pathway GLP-1 receptor agonist Dual GIP and GLP-1 receptor agonist Weight-management brand Wegovy Zepbound Diabetes brand with the same active ingredient Ozempic Mounjaro Current weight-management forms Injection and tablet Injection Direct 72-week obesity trial 13.7% mean weight reduction 20.2% mean weight reduction Notable FDA-labeled consideration Major cardiovascular event risk reduction in certain adults with established cardiovascular disease and overweight or obesity Moderate to severe obstructive sleep apnea in adults with obesity Main tolerability concern Gastrointestinal symptoms Gastrointestinal symptoms SURMOUNT-5 was a randomized phase 3b trial of adults with obesity without diabetes treated with maximum tolerated doses for 72 weeks